Compare FEAM & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | INKT |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.2M | 70.6M |
| IPO Year | N/A | 2021 |
| Metric | FEAM | INKT |
|---|---|---|
| Price | $1.48 | $11.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.38 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 197.1K | 24.9K |
| Earning Date | 05-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $6.80 |
| 52 Week High | $7.50 | $76.00 |
| Indicator | FEAM | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 48.45 |
| Support Level | $1.48 | $10.82 |
| Resistance Level | $2.10 | $12.45 |
| Average True Range (ATR) | 0.12 | 0.69 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 49.01 | 34.57 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.